Extended Data Fig. 9: Effect of small molecule modulators of STAT3 or STAT1/2 activity.
a, Representative immunofluorescence images of phospho-STAT3 (Y705) staining in vehicle control vs. IL-1α+TNF+ C1q-treated iAstrocytes. Scale bar corresponds to 20 μm. b, Phospo-STAT3 (Y705) levels measured by flow cytometry in iAstrocytes treated with vehicle control vs. IL-1α+TNF+ C1q in the presence of increasing doses of napabucasin (n = 6 wells for 0 μM napabucasin, n = 3 for napabucasin > 0 μM). MFI: median fluorescence intensity. c, Percent VCAM1−/C3+, VCAM1+ /C3−, or VCAM1+ /C3+ cells measured by flow cytometry)in iAstrocytes treated with vehicle control vs. IL-1α+TNF+ C1q in the presence of increasing doses of napabucasin (n = 6 wells for 0 μM napabucasin, n = 3 for napabucasin > 0 μM). d, Percent VCAM1−/C3+, VCAM1+ /C3−, or VCAM1+ /C3+ cells measured by flow cytometry in iAstrocytes treated with vehicle control vs. IL-1α+TNF+ C1q, with or without concurrent RGFP966 treatment (n = 6 wells). In panels b-d, P values were calculated using linear regression for MFI values or beta regression (two-sided Wald test; see Methods) for percentages and adjusted for multiple testing (Padj; Holm’s method) per family of tests (all comparisons within a plot).
